跳至主要内容
临床试验/JPRN-UMIN000021596
JPRN-UMIN000021596已完成2 期

Community-based study about the efficacy of Melissa officinalis extract which contained rosmarinic acid on cognitive function in older adults with subjective cognitive impairment and mild cognitive impairment: A double blind, placebo-controlled, parallel-design, randomized control trial - Noto Rosmarinic Acid Project for Prevention of Dementia

Department of Neurology and Neurobiology of Aging, Kanazawa university Graduate School of Medical Science0 个研究点目标入组 330 人开始时间: 2016年3月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Subjects who have mental illness such as schizophrenia, bipolar disorder, depression etc. based on the diagnostic criteria of DSM-5 2. GDS-15 score more than 6 points at screening test 3. Subjects with uncontrolled health problem such as diabetes mellitus, hypertension, heart failure, angina pectoris, renal dysfunction, etc.. within 3 months before screening period. The researcher determines that there is a medically significant risk 4. Subjects who has malignancy within 5 years before screening period. Except for the low risk of recurrence cases who has no recurrence for 3 years. The researcher must determine whether to exclude the subjects with malignancy 5. Subjects administrated the prohibited concomitant therapy within prohibition period shown in Table1 6. Subjects who has previous history of alcohol and/or drug abuse 7. Subjects who has hypersensitivity to polyphenols 8. Subjects who has drug and/or food allergy 9. The subjects judged to inadequacy by the researcher Table1. Prohibited concomitant therapy (Prohibition period) Cholinesterase inhibitors and glutamate NMDA receptor antagonist (3 months) Daily administration of anticholinergic drugs (4 weeks) Antidepressant drugs (4 weeks) Antipsychotic drugs (4 weeks) Mood-stabilizing drugs and anticonvulsants (4 weeks) Daily administration of hypnotic, sedative/benzodiazepines (4 weeks) Daily administration of narcotic analgesics (4 weeks) Anti-Parkinson's disease treatment drugs (3 months)

研究者

发起方
Department of Neurology and Neurobiology of Aging, Kanazawa university Graduate School of Medical Science

相似试验